- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.10. | Ascelia Pharma Provides Orviglance Update Following FDA Type a Meeting | 680 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / October 11, 2026 / Ascelia Pharma (STO:ACE) - Ascelia Pharma AB (publ) today announces that it has received the official minutes from its Type A meeting with the U.S. Food... ► Artikel lesen | |
| 24.09. | Ascelia Pharma Announces Publication of Orviglance Clinical Study in Journal of Magnetic Resonance Imaging | 294 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / September 24, 2026 / Ascelia Pharma AB (publ) (STO:ACE), a biotech company focused on improving the lives of people living with rare cancer conditions, today announced... ► Artikel lesen | |
| 10.09. | Ascelia Pharma Completes FDA Type A Meeting on Orviglance NDA | 430 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / September 10, 2026 / Ascelia Pharma (STO:ACE) completed the previously scheduled Type A meeting with the U.S. Food and Drug Administration (FDA) on September 9, 2026, regarding... ► Artikel lesen | |
| 21.08. | Ascelia Pharma Q2 2026 slides: FDA meeting key after Orviglance setback | 1 | Investing.com | ||
| 20.08. | Ascelia Pharma: Focus on The Path Forward for Orviglance | 365 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / August 20, 2026 / Ascelia Pharma (STO:ACE) today published its Half-Year Report for 2026 (January - June), which is now available on the company's website: Financial Reports... ► Artikel lesen | |
| 20.08. | Ascelia Pharma AB: Focus on the Path Forward for Orviglance | 268 | GlobeNewswire (Europe) | Ascelia Pharma AB (publ) (ticker: ACE) today published its Half-Year Report for 2026 (January - June), which is now available on the company's website: Financial Reports - ASCELIA
KEY EVENTS IN Q2 2026Ascelia... ► Artikel lesen | |
| ASCELIA PHARMA Aktie jetzt für 0€ handeln | |||||
| 17.08. | Ascelia Pharma Announces FDA Has Scheduled Type A Meeting for Orviglance NDA on September 9, 2026 | 1.070 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / August 17, 2026 / Ascelia Pharma AB (publ) (STO:ACE), a biotech company focused on improving the lives of people living with rare cancer conditions, today announced that... ► Artikel lesen | |
| 15.07. | Ascelia Pharma Announces Organizational Changes and a Reduced Cost Base | 545 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / July 15, 2026 / Ascelia Pharma (STO:ACE), a biotech company focused on improving the lives of people with rare cancer conditions, today announces that CFO Anton Hansson... ► Artikel lesen | |
| 15.07. | Ascelia Pharma AB: Ascelia Pharma Announces Organizational Changes and a Reduced Cost Base | 486 | GlobeNewswire (Europe) | Ascelia Pharma AB (publ) (ticker: ACE), a biotech company focused on improving the lives of people with rare cancer conditions, today announces that CFO Anton Hansson will be leaving the Company. In... ► Artikel lesen | |
| 12.07. | Ascelia Pharma Provides Orviglance Update | 1.080 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / July 12, 2026 / Ascelia Pharma (STO:ACE) - Ascelia Pharma AB (publ) (STO:ACE), a biopharmaceutical company focused on improving the lives of people living with rare cancer... ► Artikel lesen | |
| 03.07. | Ascelia Pharma Provides Update on the Orviglance NDA | 865 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / July 3, 2026 / Ascelia Pharma AB (publ) (STO:ACE), a biotechnology company focused on improving the lives of people living with rare cancer conditions, today announced... ► Artikel lesen | |
| 03.07. | Ascelia Pharma AB: Ascelia Pharma provides update on the Orviglance NDA | 916 | GlobeNewswire (Europe) | Ascelia Pharma AB (publ) (ticker: ACE), a biotechnology company focused on improving the lives of people living with rare cancer conditions, today announced that it has received a Complete Response... ► Artikel lesen | |
| 30.06. | Ascelia Pharma Expands Orviglance IP Portfolio with New Patent Filing | 552 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / June 30, 2026 / Ascelia Pharma AB (publ) (STO:ACE), a biotech company focused on improving the life of people living with rare cancer conditions, today announced the filing... ► Artikel lesen | |
| 09.06. | Ascelia Pharma: Orviglance Data Presented Today at the Annual Radiology Congress ESGAR 2026 | 471 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / June 9, 2026 / Ascelia Pharma AB (publ)(STO:ACE) announces that Orviglance data will be presented as an oral presentation today at the European Society of Gastrointestinal... ► Artikel lesen | |
| 12.05. | Ascelia Pharma: Quarterly Report Q1 2026: Orviglance Approaching Transformative Milestones | 666 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / May 12, 2026 / Ascelia Pharma AB (publ) (STO:ACE) today published its Interim Report Q1 for 2026 (January - March), which is now available on the company's website: Financial... ► Artikel lesen | |
| 04.05. | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 4 May 2026 | 473 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / May 4, 2026 / Ascelia Pharma (STO:ACE) - Today, on 4 May 2026, an annual general meeting was held in Ascelia Pharma AB. A summary of the adopted resolutions follows below.... ► Artikel lesen | |
| 30.04. | Change in Number of Shares and Votes in Ascelia Pharma AB | 417 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / April 30, 2026 / Ascelia Pharma (STO:ACE):During April, the registered number of shares and votes in Ascelia Pharma AB ("Ascelia Pharma") has increased due to the directed... ► Artikel lesen | |
| 09.04. | Ascelia Pharma: Annual Report 2025: Orviglance NDA submitted to the FDA, PDUFA-date set for July 2026 | 828 | ACCESS Newswire | The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. MALMÖ, SE / ACCESS Newswire / April... ► Artikel lesen | |
| 30.03. | Notice of Annual General Meeting in Ascelia Pharma AB | 434 | ACCESS Newswire | The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. MALMÖ, SE / ACCESS Newswire / March... ► Artikel lesen | |
| 27.03. | Ascelia Pharma Announces Acceptance of Orviglance Data for Oral Presentation at the Annual Radiology Congress ESGAR 2026 | 634 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / March 27, 2026 / Ascelia Pharma (STO:ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that an abstract with an... ► Artikel lesen |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 35,300 | +0,44 % | Novo Nordisk muss zittern: Eli Lilly vor Milliardenchance: Neue Abnehmpille nimmt wichtige EU-Hürde! | Eli Lillys Abnehmpille Foundayo nimmt eine wichtige EU-Hürde. Die mögliche Zulassung verschärft den Milliardenwettbewerb mit Novo Nordisk Enthaltene Werte: US5324571083,DK0062498333Den vollständigen... ► Artikel lesen | |
| PFIZER | 27,095 | -0,06 % | Community Rückblick: BioNTech BNT113 Studie verfehlt Endpunkt: "Die Bude treibt einen zum Wahnsinn!" | © Foto: Julia Cebella - dpaBioNTech verfehlt mit BNT113 ein wichtiges Studienziel. Im wO-Forum streiten Anleger über die Zukunft der mRNA-Krebsforschung, die Bewertung der Aktie und das Potenzial der... ► Artikel lesen | |
| NOVARTIS | 139,86 | +0,40 % | RBC stuft NOVARTIS AG auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat die Einstufung für Novartis vor Zahlen für das dritte Quartal auf "Sector Perform" mit einem Kursziel von 120 Franken belassen. Der Pharmakonzern... ► Artikel lesen | |
| MERCK & CO | 131,36 | +0,06 % | Aktien New York: Kursrutsch an der Nasdaq - KI-Sorgen und steigende Ölpreise | NEW YORK (dpa-AFX) - Deutlich gestiegene Ölpreise und negativ aufgenommene Investitionspläne des Technologiekonzerns Meta haben der Nasdaq-Börse am Donnerstag wieder einen kräftigen Dämpfer verpasst.... ► Artikel lesen | |
| TEVA PHARMACEUTICAL INDUSTRIES | 40,180 | -0,04 % | Teva/Sanofi: Duvakitug Maintains Meaningful Efficacy Improvements In Long-term Extension Study | PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), and Sanofi announced new positive data from the RELIEVE UCCD phase 2b long-term extension... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 50,13 | +0,22 % | Biotech Stocks At 52-Week Highs - Eton Pharmaceuticals +44%, DexCom, Oruka Therapeutics, Concentra Group Holdings Parent, AtaiBeckley | INDIANAPOLIS (dpa-AFX) - The following biotech stocks reached 52-week highs on August 14, 2026, following positive quarterly reports or an announced upcoming acquisition. Eton Pharmaceuticals... ► Artikel lesen | |
| GSK | 22,840 | 0,00 % | JEFFERIES stuft GSK auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für GSK nach Studiendaten für das Krebs-Konjugat Risvutatug Rezetecan mit einem Kursziel von 2500 Pence auf "Buy" belassen.... ► Artikel lesen | |
| IAMBIC THERAPEUTICS | 14,520 | -1,02 % | Biotech an der Börse: Iambic-IPO bringt 150 Millionen USD für Krebsmedikamente | Das US-Biotechunternehmen Iambic setzt bei neuen Krebsmedikamenten auf künstliche Intelligenz. Mit dem frischen Börsenkapital will es klinische Studien voranbringen und seine Forschungstechnik ausbauen.... ► Artikel lesen | |
| BAYER | 44,120 | -0,20 % | Bayer: Wird Nubeqa zum größten Medikament der Firmengeschichte? | Auf dem Krebskongress ESMO stehen Zwischendaten zu Bayers Prostatakrebsmittel Nubeqa an. Die BofA rechnet mit einem klaren Erfolg und traut dem Medikament den Rekord in der Konzerngeschichte zu. Bayer... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,130 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung für Aquestive nach FDA-Fortschritten | ||
| GENERATE BIOMEDICINES | 12,800 | +0,08 % | Generate Biomedicines, Inc.: Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of 'Armored' CAR T Therapy for Ovarian Cancer | Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials First patient treated in new clinical... ► Artikel lesen | |
| LB PHARMACEUTICALS | 39,460 | +0,10 % | Stifel reiterates Buy rating on LB Pharmaceuticals stock at $53 | ||
| KARDIGAN | 12,740 | 0,00 % | Baird stuft Kardigan mit "Outperform" ein - Kursziel 43 US-Dollar | ||
| OMNIAB | 4,770 | -0,21 % | OmniAb auf der LD Micro Konferenz: Lizenzgebühren, Skalierung und Geduld im Fokus | ||
| BRIGHT MINDS BIOSCIENCES | 52,50 | -0,36 % | Levoit and Cosori: 5 Back to School Wellness Heroes for the Bright Minds of Tomorrow | DUBAI, UAE, Aug. 21, 2026 /PRNewswire/ -- Levoit and Cosori unveil five smart home solutions to tackle back to school stresses: polluted indoor air, relentless AC dryness, post snack floor... ► Artikel lesen |
ASCELIA PHARMA AB gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von +0,000 (+0,80 %) liegt der Kurs bei 0,038 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ASCELIA PHARMA AB finden Sie auf Wallstreet Online.